New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
08:01 EDTAMGN, BINDBIND Therapeutics maintained as an Outperform, says Credit Suisse
Amgen (AMGN) declined to exercise its option on BIND Therapeutics' Accurin technology following completion of the collaboration. Credit Suisse does not view this as a negative read through for BIND-014 and continues to believe the technology is a valuable platform and expects Ph II results for BIND-014 in 2H 2014 to be a catalyst. The firm maintains its Outperform rating but lowers its price target to $20 from $21.
News For BIND;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 24, 2015
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
June 23, 2015
09:14 EDTBINDOn The Fly: Pre-market Movers
Subscribe for More Information
07:31 EDTBINDBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTAMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
10:16 EDTBINDBIND Therapeutics names Andrew Hirsch as president and CEO
BIND Therapeutics announced that Andrew Hirsch has been appointed president and CEO of the company. Hirsch had been serving in the role on an acting basis since March. Hirsch has also been elected to BIND’s Board of Directors. “After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the company’s growth,” said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors.
June 19, 2015
16:02 EDTAMGNAmgen presents open-label extension data for Phase 2 study of migraine treatment
Subscribe for More Information
07:23 EDTAMGNTeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use